Previous close | 7.04 |
Open | 7.04 |
Bid | 6.98 x 200 |
Ask | 7.14 x 100 |
Day's range | 6.80 - 7.15 |
52-week range | 2.44 - 8.84 |
Volume | |
Avg. volume | 153,249 |
Market cap | 353.586M |
Beta (5Y monthly) | 1.42 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Monte Rosa Therapeutics (GLUE) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Advances in Clinical Trials and Strategic Collaboration Mark Year's Achievements